Use of Radionuclides in Experimental Vascular Thrombosis

  • Linda W. Schaffer
  • John T. Davidson
  • Peter K. S. Siegl


Vaso-occlusive thrombosis resulting in ischemic cardiovascular, cerebrovascular, and peripheral vascular disease is a leading cause of mortality in the world (Collen and Gold, 1990). Arterial high shear conditions promote the formation of thrombus composed primarily of platelets, while low shear venous conditions promote the formation of thrombus composed primarily of fibrin and red blood cells (Cadroy and Harker, 1990). The critical role of platelets and fibrin in the pathogenesis of vascular thrombosis make these two components of the hemostatic system ideal targets for radiolabeling to facilitate study of the effects of pharmacological intervention on experimental thrombosis. In this chapter, we describe the systemic application of nuclear medicine technology to assess the antithrombotic efficacy of putative therapeutic agents in a baboon model of platelet-dependent vascular graft thrombosis.


Arteriovenous Shunt Platelet Deposition Baboon Model Antithrombotic Efficacy Thrombus Imaging 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Atkins P and Hawkins LA (1965): Detection of venous thrombosis in the legs. Lancet 2:1216–1219.Google Scholar
  2. Bates ER, McGillem MJ, Mickelson JK, Pitt B and Mancini GJ (1991): A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 84:2463–2469.Google Scholar
  3. Bauman JM, and Landry AJ (1986): Practical platelet labeling with Indium111 oxine. J Nucl Med Tech 14: 15–17.Google Scholar
  4. Beckerman C (1984): The fibrinogen uptake test and fibrinogen scintography for detection of deep vein thrombosis. In: Imaging of the Peripeheral Vascular System, Pinsky SM and Moss GS, eds. Orlando: Grune and Stratton, Inc.Google Scholar
  5. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Thibult N, Touboul D and Touboul PJ (1983): “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 14: 5–14.Google Scholar
  6. Bush LR and Shebuski RJ (1990): In vivo models of arterial thrombosis and thrombolysis. FASEB J 4: 3087–3098.Google Scholar
  7. Cadroy YC, Houston RA and Hanson SR (1989a): RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. J Clin Invest 84: 939–944.CrossRefGoogle Scholar
  8. Cadroy Y, Harker LA and Hanson SR (1989b): Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): Comparison with standard heparin. J Lab Clin Med 114: 349–357.Google Scholar
  9. Cadroy Y and Harker LA (1990): Platelets, thrombosis and antithrombotic therapies. In: Cardiovascular Pharmacology, Antonaccio M, ed. New York: Raven Press, Ltd.Google Scholar
  10. Callow AD, Ledig CB, O’Donnell TF, Kelly JJ, Rosenthal D, Korwin S, Hatte C, Kahn PC, Vecchione JJ and Valeri CR (1980): A primate model for the study of the interaction of min-labeled baboon platelets with Dacron arterial protheses. Ann Surg 191: 362–366.CrossRefGoogle Scholar
  11. Cerqueira MD, Stratton JR, Vracko R, Schaible TF and Ritchie JL (1992): Noninvasive arterial thrombus imaging with 99mTc monoclonal antifibrin antibody. Circulation 85: 298–304.Google Scholar
  12. Collen D and Gold HK (1990): New developments in thrombolytic therapy. Adv Exp Med Biol 281: 333–354.CrossRefGoogle Scholar
  13. Coller BS, Folts JD, Smith SR, Scudder LE and Jordan R (1989): Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Circulation 80: 1766–1774.CrossRefGoogle Scholar
  14. DeNardo SJ, DeNardo GL, O’Brien T, Peek NF, Zielinski FW and Jungerman JA (1974): 1–123 fibrinogen imaging of thrombi in dogs. J Nucl Med 15: 487.Google Scholar
  15. Didisheim P (1972): Animal models useful in the study of thrombosis and antithrombotic agents. Prog Hemostasis Thromb 1: 165–197.Google Scholar
  16. Dunwiddie C, Thornberry NA, Bull HG, Sardana M, Friedman PA, Jacobs JW and Simpson E (1989): Antistasin, a leech-dervied inhibitor of factor Xa. J Biol Chem 264: 16694–16699.Google Scholar
  17. Eidt JF, Allison P, Noble S, Ashton J, Golino P, McNatt J, Buja LM and Willerson JT (1989): Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 84: 18–247.CrossRefGoogle Scholar
  18. Fressinaud E, Baruch D, Rothschild C, Baumgartner HR and Meyer D (1987): Platelet von Willebrand factor: Evidence for its involvement in platelet adhesion to collagen. Blood 70: 1214–1217.Google Scholar
  19. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ and Chesebro JH (1990): Atherosclerotic plaque rupture and thrombosis. Circulation 82 (suppl II): II-47–II-59.Google Scholar
  20. George, JN (1990): Hemostasis and fibrinolysis. In: Internal Medicine, Stein JH, ed. Little, Brown and Company.Google Scholar
  21. Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA and Collen D (1988): Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77: 670–677.CrossRefGoogle Scholar
  22. Gruber A, Hanson SR, Kelly AB, Yar BS, Bang N, Griffin JH and Harker LA (1990): Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 82: 578–585.CrossRefGoogle Scholar
  23. Hanson SR and Harker LA (1985): Studies of suloctodil in experimental thrombosis in baboons. Thromb Haemostasis 53:423–427.Google Scholar
  24. Hanson SR, Kotze HR, Savage B and Harker LA (1985a): Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 5: 595–603.CrossRefGoogle Scholar
  25. Hanson SR, Harker LA and Bjomsson TD (1985b): Effects of platelet-modifying drugs on arterial thromboembolism in baboons. J Clin Invest 75: 1591–1599.CrossRefGoogle Scholar
  26. Hanson SR and Harker LA (1988): Interruption of acute platelet-dependent thrombosis by the synthetic anti-thrombin D-phenylalanyl-L-prolyl-L-arginyl chloro-methyl ketone. Proc Natl Acad Sci 85: 3184–3188.CrossRefGoogle Scholar
  27. Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmerman TS and Harker LA (1988): Effects of monoclonal antibodies against the platelet glycoprotein Ilb/IIIa complex on thrombosis and hemostasis in baboons. J Clin Invest 81: 149–158.CrossRefGoogle Scholar
  28. Harker LA, Kelly AB and Hanson SR (1991): Experimental arterial thrombosis in nonhuman primates. Circulation 83 (suppl IV): IV42–IV55.Google Scholar
  29. Harker LA and Hanson SR (1979): Experimental arterial thromboembolism in baboons: Mechanism, quantitation and pharmacological prevention. J Clin Invest 64: 559–569.CrossRefGoogle Scholar
  30. Haskel EJ, Prager NA, Sobel BE and Abendschein DR (1991): Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83: 1048–1056.Google Scholar
  31. Haskel EJ, Adams SP, Feigen LP, Saffitz JE, Gorczynski RJ, Sobel BE and Abendschein DR (1989): Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation 80:1775–1782.CrossRefGoogle Scholar
  32. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L and Fuster V (1989): Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79: 657–665.CrossRefGoogle Scholar
  33. Heras HM, Chesebro JH, Penny WJ, Bailey KR, Lam JYT, Holmes DR, Reeder GS, Badimon L and Fuster V (1988): The importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 78: 654–660.CrossRefGoogle Scholar
  34. Heras M, Chesebro JH, Webster MW, Mruk JS, Grill DE, Penny WJ, Bowie EJ, Badimon L and Fuster V (1990): Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 82: 1476–1484.CrossRefGoogle Scholar
  35. Hobb JT and Davies JWL (1960): Detection of venous thrombosis with 131I-labeled fibrinogen in the rabbit. Lancet 2: 134.CrossRefGoogle Scholar
  36. Jakobsen E and Kierulf P (1973): A modified β-alanine precipitation procedure to prepare fibrinogen free of antithrombin III and plasminogen. Thromb Res 3: 145–149.CrossRefGoogle Scholar
  37. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT and Collen D (1990): Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 81: 219–225.CrossRefGoogle Scholar
  38. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR and Harker LA (1991): Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 77: 1006–1017.Google Scholar
  39. Knight LC, Budzynski AZ and Olexa SA (1981): Radiolabeling of fibrinogen using the iodogen technique. Thromb Haemostasis 46: 593–596.Google Scholar
  40. Knight L (1990): Radiopharmaceuticals for thrombus detection. Semin Nucl Med 20:52–67.CrossRefGoogle Scholar
  41. Koblik PD, DeNardo GL and Berger HJ (1989): Current status of immunoscintigraphy in the detection of thrombosis and thromboembolism. Semin Nucl Med 19:221–237.CrossRefGoogle Scholar
  42. Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L and Fuster V (1986): Deep arterial injury during experimental angioplasty: Relationship to positive 111Indium-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 8:1380–1386.CrossRefGoogle Scholar
  43. Lotter MG (1985): Measurement of platelet survival and analysis of survival curves. In: Platelet Kinetics and Imaging, Vol 1, Heyns A, Badenhorst PN and Lotter MG, eds. Boca Raton, FA: CRC Press, Inc.Google Scholar
  44. Mickelson JK, Simpson PJ and Lucchesi BR (1989): Antiplatelet monoclonal F(ab’)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 21:393–405.CrossRefGoogle Scholar
  45. Muller DW, Ellis SG and Topol EG (1992): Experimental models of coronary artery restenosis. J Am Coll Cardiol 19:418–432.CrossRefGoogle Scholar
  46. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardina M, Ellis RW, Schaffer LW, Siegl PKS and Vlasuk GP (1990): Characterization of recombinant tick anticoagulant peptide. J Biol Chem 265: 17746–17752.Google Scholar
  47. Owen J, Kvam D, Nossel HL, Kaplan KL and Kernoff PBA (1983): Thrombin and plasmin activity and platelet activation in the development of venous thrombosis. Blood 61: 476–482.Google Scholar
  48. Plow EF, Marquerie G and Ginsberg M (1987): Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 36: 4035–4040.CrossRefGoogle Scholar
  49. Schaffer LW, Davidson JT, Vlasuk GP, Dunwiddie CT and Siegl PKS (1992): Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons. Arteriosclerosis Thromb 12: 879–885.CrossRefGoogle Scholar
  50. Schaffer LW, Davidson JT, Vlasuk GP and Siegl PKS (1991): Antithrombotic efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 84: 1741–1748.Google Scholar
  51. Shebuski RJ, Ramjit DR, Sitko GR, Lumma PK and Garsky VM (1990): Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus. Thromb Haemostasis 64:576–581.Google Scholar
  52. Sitko GR, Ramjit DR, Stabilito II, Lehman DD, Lynch JJ and Vlasuk GP (1992): Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Circulation 85: 805–815.Google Scholar
  53. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE and Shebuski JR (1991): Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective FXa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemostasis 65: 257–262.Google Scholar
  54. Waxman L, Smith DE, Arcuri KE and Vlasuk GP (1990): Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 248:593–596.CrossRefGoogle Scholar
  55. Weitz JI, Hudoba M, Massel D, Maraganore J and Hirsh J (1990): Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 86:385–391.CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Linda W. Schaffer
    • 1
  • John T. Davidson
    • 1
  • Peter K. S. Siegl
    • 1
  1. 1.Departments of Pharmacology and RadiopharmacologyMerck Research LaboratoriesUSA

Personalised recommendations